{Reference Type}: Journal Article
{Title}: Specific inhibition of α-synuclein oligomer generation and toxicity by the chaperone domain Bri2 BRICHOS.
{Author}: Adam L;Kumar R;Arroyo-Garcia LE;Molenkamp WH;Nowak JS;Klute H;Farzadfard A;Alkenayeh R;Nielsen J;Biverstål H;Otzen DE;Johansson J;Abelein A;
{Journal}: Protein Sci
{Volume}: 33
{Issue}: 8
{Year}: 2024 Aug
{Factor}: 6.993
{DOI}: 10.1002/pro.5091
{Abstract}: Protein misfolding and aggregation are involved in several neurodegenerative disorders, such as α-synuclein (αSyn) implicated in Parkinson's disease, where new therapeutic approaches remain essential to combat these devastating diseases. Elucidating the microscopic nucleation mechanisms has opened new opportunities to develop therapeutics against toxic mechanisms and species. Here, we show that naturally occurring molecular chaperones, represented by the anti-amyloid Bri2 BRICHOS domain, can be used to target αSyn-associated nucleation processes and structural species related to neurotoxicity. Our findings revealed that BRICHOS predominantly suppresses the formation of new nucleation units on the fibrils surface (secondary nucleation), decreasing the oligomer generation rate. Further, BRICHOS directly binds to oligomeric αSyn species and effectively diminishes αSyn fibril-related toxicity. Hence, our studies show that molecular chaperones can be utilized as tools to target molecular processes and structural species related to αSyn neurotoxicity and have the potential as protein-based treatments against neurodegenerative disorders.